||WO||WO/2013/033656 - METHODS FOR THE TREATMENT OF BREAST CANCER||07.03.2013||
||PCT/US2012/053551||SYNDAX PHARMACEUTICALS, INC.||GOODENOW, Robert|
Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.
||WO||WO/2012/150967 - IMPROVED POLYMERIC COMPOSITION FOR CEMENT BASED SUBSTRUCTURES||08.11.2012||
||PCT/US2012/000231||UNISEAL SOLUTIONS INC.||LEAMAN, Michael, Ray|
The present invention is directed to a composition capable of inhibiting moisture vapor emission from concrete structures and enhancing adhesion of a finish material to the concrete structure comprising an aqueous mixture of a first copolymer of mer units formed from vinylidene halide and a C1-C2 alkyl acrylate with a second copolymer of mer units formed from vinylidene halide and a C4-CS alkyl acrylate and to the method of forming a moisture barrier/adhesion promoter coating on concrete comprising applying from 2.8 to 5.6 liters (0.75 to 1.5 gallons) of an aqueous carrier having from 10 to 50 weight percent of the mixture of copolymers stated above per 14 m2 (150 square feet) of the free surface of a concrete structure.
||WO||WO/2012/151326 - METHOD OF TREATING CANCER AND BONE CANCER PAIN||08.11.2012||
||PCT/US2012/036191||EXELIXIS, INC.||SCHWAB, Gisela|
This invention is directed to the treatment of cancer, particularly lung cancer, breast cancer, melanoma, renal cell carcinoma, thyroid cancer that has metastasized to the bone. The invention is also directed to a method for treating bone cancer pain in an individual in need of such treatment comprising administering to the individual an effective amount of a compound of Formula I.
||WO||WO/2012/151248 - FORMULATION FOR ANTI-α4β7 ANTIBODY||08.11.2012||
||PCT/US2012/036072||MILLENNIUM PHARMACEUTICALS, INC.||DILUZIO, Willow|
Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
||WO||WO/2012/146736 - USE OF 3-CARBOXY-N-ETHYL-N,N-DIMETHYLPROPAN-1-AMINIUM SALTS IN THE TREATMENT OF CARDIOVASCULAR DISEASE||01.11.2012||
||PCT/EP2012/057806||GRINDEKS, A JOINT STOCK COMPANY||KALVINS, Ivars|
Salts of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium, method of preparation thereof and use in the treatment of cardiovascular disease.
||WO||WO/2012/137089 - PYRROLO [2, 3 -D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES||11.10.2012||
||PCT/IB2012/051363||PFIZER LIMITED||ANDREWS, Mark David|
The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
||WO||WO/2012/133918 - SOLID PREPARATION||04.10.2012||
||PCT/JP2012/059276||TAKEDA PHARMACEUTICAL COMPANY LIMITED||HOSHINA, Wataru|
The present invention provides a solid preparation wherein variation in weight is suppressed, a solid preparation wherein the active ingredient is stabilized, and a stabilization method thereof. A solid preparation containing (1) an active ingredient, (2) D-mannitol and (3) an alkaline earth metal salt selected from magnesium aluminometasilicate and calcium silicate. A method of stabilizing the. active ingredient, including adding an alkaline earth metal salt selected from magnesium aluminometasilicate and calcium silicate.
||WO||WO/2012/131379 - THIENO [2, 3 -D] PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA||04.10.2012||
||PCT/GB2012/050710||XENTION LIMITED||JOHN, Derek Edward|
The present invention relates to thienopyrimidine compounds which are potassium channel inhibitors. Pharmaceutical compositions comprising the compounds and their use in the treatment of arrhythmia are also described.
||WO||WO/2012/134526 - METHOD AND SYSTEM FOR TREATING WATER USED FOR INDUSTRIAL PURPOSES||04.10.2012||
||PCT/US2011/051236||CRYSTAL LAGOONS (CURACAO) B.V.||FISCHMANN T., Fernando|
A low cost method and system for treating water, which will be used in an industrial process, is provided. A system of the invention generally includes at least one containing means, at least one coordination means, at least one chemical application means, at least one mobile suction means, and at least one filtration means. The coordination means can control the necessary processes depending on the system needs (e.g., water quality or purity). The method and system of the invention purifies the water and eliminates suspended solids without the need of filtering the totality of the water volume, but only filtering a small fraction of up to 200 times less than the flow filtered by a conventional water treatment filtration system.
||WO||WO/2012/134527 - SUSTAINABLE METHOD AND SYSTEM FOR TREATING WATER BODIES AFFECTED BY BACTERIA AND MICROALGAE AT LOW COST||04.10.2012||
||PCT/US2011/051244||CRYSTAL LAGOONS (CURACAO) B.V.||FISCHMANN, T., Fernando|
A system for treating and maintaining bodies of water for low density recreational use is disclosed. A system of the invention generally includes containing means, coordination means, chemical application means, non-intrusive mobile suction means, and filtration means. The coordinating means can receive information regarding controlled water quality parameters, and can timely activate the processes necessary to adjust the water quality parameters within their respective limits. The disclosed system filters only a small fraction of the total water volume, up to 200 times less per day than the flow filtered by conventional swimming pool filtration systems. The disclosed methods and system also use less chemicals than conventional swimming pool water treatment systems. The system of the present invention can be used to treat recreational water bodies and provide sustainable methods for producing water that meets Environmental Protection Agency (EPA) requirements for recreational water, for bathing with full body contact.